U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C4H10N2.BrH
Molecular Weight 167.048
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PIPERAZINE HYDROBROMIDE

SMILES

Br.C1CNCCN1

InChI

InChIKey=RYHBGVSBFUOHAE-UHFFFAOYSA-N
InChI=1S/C4H10N2.BrH/c1-2-6-4-3-5-1;/h5-6H,1-4H2;1H

HIDE SMILES / InChI

Molecular Formula BrH
Molecular Weight 80.912
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C4H10N2
Molecular Weight 86.1356
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/27177234 |

Piperazine, a six membered nitrogen containing heterocycle, is of great significance to the rational design of drugs. This moiety can be found in a plethora of well-known drugs with various therapeutic uses, such as antipsychotic, antihistamine, antianginal, antidepressant, anticancer, antiviral, cardio protectors, anti-inflammatory, and imaging agents. Slight modification to the substitution pattern on the piperazine nucleus facilitates a recognizable difference in the medicinal potential of the resultant molecules. Piperazine has been used as an antihelmintic drug. Piperazine works by paralyzing the worms. They are then passed in the stool.

CNS Activity

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: UniProtKB: D6BK80_HAECO | D6BJF3_HAECO (GABA receptor subunit)
6.23 mM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
MULTIFUGE

Approved Use

Piperazine belongs to the family of medicines called anthelmintics. Anthelmintics are used in the treatment of worm infections. Piperazine is used to treat: common roundworms (ascariasis) and pinworms (enterobiasis; oxyuriasis).

Launch Date

-4.88332788E11
Doses

Doses

DosePopulationAdverse events​
10 mg/m3/h single, respiratory
Studied dose
Dose: 10 mg/m3/h
Route: respiratory
Route: single
Dose: 10 mg/m3/h
Sources:
unhealthy, 42 years
n = 1
Health Status: unhealthy
Condition: Occupational asthma
Age Group: 42 years
Sex: F
Population Size: 1
Sources:
Other AEs: Asthma late onset...
Other AEs:
Asthma late onset (1 patient)
Sources:
115 mg/kg 1 times / day steady, oral
Highest studied dose
Dose: 115 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 115 mg/kg, 1 times / day
Sources:
unhealthy, 6 years
n = 1
Health Status: unhealthy
Condition: abdominal pain due to probable worm infestation
Age Group: 6 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Myoclonus...
AEs leading to
discontinuation/dose reduction:
Myoclonus (1 patient)
Sources:
65 mg/kg 1 times / day steady, oral
Recommended
Dose: 65 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 65 mg/kg, 1 times / day
Sources:
unhealthy, 9 years
n = 1
Health Status: unhealthy
Condition: pinworm or roundworm infections
Age Group: 9 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Ataxia...
AEs leading to
discontinuation/dose reduction:
Ataxia (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Asthma late onset 1 patient
10 mg/m3/h single, respiratory
Studied dose
Dose: 10 mg/m3/h
Route: respiratory
Route: single
Dose: 10 mg/m3/h
Sources:
unhealthy, 42 years
n = 1
Health Status: unhealthy
Condition: Occupational asthma
Age Group: 42 years
Sex: F
Population Size: 1
Sources:
Myoclonus 1 patient
Disc. AE
115 mg/kg 1 times / day steady, oral
Highest studied dose
Dose: 115 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 115 mg/kg, 1 times / day
Sources:
unhealthy, 6 years
n = 1
Health Status: unhealthy
Condition: abdominal pain due to probable worm infestation
Age Group: 6 years
Sex: F
Population Size: 1
Sources:
Ataxia 1 patient
Disc. AE
65 mg/kg 1 times / day steady, oral
Recommended
Dose: 65 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 65 mg/kg, 1 times / day
Sources:
unhealthy, 9 years
n = 1
Health Status: unhealthy
Condition: pinworm or roundworm infections
Age Group: 9 years
Sex: M
Population Size: 1
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast cancer.
2001
Endoscopic carpal tunnel release and nerve conduction studies.
2001
Synthesis and evaluation of radiolabeled piperazine derivatives of vesamicol as SPECT agents for cholinergic neurons.
2001 Apr
Acrylamide-based monoliths as robust stationary phases for capillary electrochromatography.
2001 Apr 20
Biliary Ascariasis in children.
2001 Apr-Jun
A practical GnRH analogue (triptorelin) stimulation test to distinguish constitutional delay of puberty from hypogonadotropic hypogonadism in prepubertal boys.
2001 Apr-Jun
Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate.
2001 Aug
Diketopiperazine receptors: a novel class of highly selective receptors for binding small peptides.
2001 Aug 3
A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients.
2001 Dec
D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC Gynaecological Cancer Co-operative Group Study.
2001 Feb
The dorsal aponeurosis, intrinsic, hypothenar, and thenar musculature of the hand.
2001 Feb
Long-term remission of ovarian hyperandrogenism after short-term treatment with a gonadotropin-releasing hormone agonist.
2001 Jan
Synthesis and structure-activity relationships of a new model of arylpiperazines. 5. Study of the physicochemical influence of the pharmacophore on 5-HT(1a)/alpha(1)-adrenergic receptor affinity: synthesis of a new derivative with mixed 5-HT(1a)/d(2) antagonist properties.
2001 Jan 18
Liquid-phase parallel synthesis of ureas.
2001 Jan 22
Efficacy of nafarelin in assisted reproductive technology: a meta-analysis.
2001 Jan-Feb
N-Terminal peptide aldehydes as electrophiles in combinatorial solid phase synthesis of novel peptide isosteres.
2001 Jan-Feb
[Inactivation of Trypanosoma cruzi trypanothione reductase by phenothiazine cationic free radicals].
2001 Jan-Mar
Estrogen 'add-back' and lipid profile during GnRH agonist (triptorelin) therapy.
2001 Jul
Effect of reduced dose of triptorelin at the start of ovarian stimulation on the outcome of IVF: a randomized study.
2001 Jul
[Study on the latency difference between compound muscle and sensory nerve action potentials].
2001 Jun
Isolation and identification of clozapine metabolites in patient urine.
2001 Jun
Chemistry of the diazeniumdiolates. 2. Kinetics and mechanism of dissociation to nitric oxide in aqueous solution.
2001 Jun 13
On the branching of motoneurons.
2001 Mar
Factors influencing agonist potency and selectivity for the opioid delta receptor are revealed in structure-activity relationship studies of the 4-[(N-substituted-4-piperidinyl)arylamino]-N,N-diethylbenzamides.
2001 Mar 15
[Decapeptyl (triptorelin) in the treatment of endometriosis genitalis externa].
2001 May
Lumbrical muscle with an additional origin in the forearm.
2001 May
Direct effects of GnRH agonists in human hormone-sensitive endometrial cells.
2001 May 15
Sex hormone replacement therapy reverses decreased venous distensibility in pharmacologically ovariectomized rats.
2001 May-Jun
N1-phenyl substituted 4-quinolones of tuberculostatic activity.
2001 Nov
Physical and chemical enhancement of transdermal delivery of triptorelin.
2001 Nov
Synthesis and antibacterial activity of some novel N-substituted piperazinyl-quinolones.
2001 Nov-Dec
Solid-phase synthesis of libraries generated from a 4-phenyl-2-carboxy-piperazine scaffold.
2001 Nov-Dec
New mu-opioid receptor agonists with piperazine moiety.
2001 Oct
Continuous beds with vancomycin as chiral stationary phase for capillary electrochromatography.
2001 Sep
Use of gonadotropin-releasing hormone analog with tibolone to prevent cyclic attacks of acute intermittent porphyria.
2001 Sep
Significance of ligand tails for interaction with the minor groove of B-DNA.
2001 Sep
Kinetics and mechanisms of the reactions of 3-methoxyphenyl, 3-chlorophenyl, and 4-cyanophenyl 4-nitrophenyl thionocarbonates with alicyclic amines.
2001 Sep 7
Improvement in the selectivity and metabolic stability of the serotonin 5-HT(1A) ligand, S 15535: a series of cis- and trans-2-(arylcycloalkylamine) 1-indanols.
2002 Jan 3
Patents

Sample Use Guides

No special preparations or other steps (for example, special diet, fasting, other medicines, laxatives, or enemas) are necessary before, during, or immediately after you take piperazine. Piperazine may be taken with or without food or on a full or empty stomach. However, if your doctor tells you to take the medicine a certain way, take it exactly as directed. For patients taking the granules for oral solution form of piperazine: Dissolve the contents of 1 packet of granules in 57 mL (about 2 ounces) of water, milk, or fruit juice. Be sure to drink all of the liquid to get the full dose of medicine. Take this medicine only as directed. Do not take more of it and do not take it more often than your doctor ordered. To do so may increase the chance of serious side effects. To help clear up your infection completely, take this medicine in regularly spaced doses as ordered by your doctor. In some infections, a second treatment with this medicine may be required to clear up the infection completely. Do not miss any doses. For patients taking piperazine for pinworms: Pinworms may be easily passed from one person to another, especially among persons in the same household. Therefore, all household members may have to be treated at the same time to prevent their infection or reinfection. Dosing The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so. The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine. For granules for oral solution dosage form: For common roundworms or pinworms: Adults and teenagers—2 grams three times a day for one day. Treatment may need to be repeated in two weeks. Children—Dose is based on age and/or body weight. Treatment may need to be repeated in two weeks. Up to 2 years of age: Dose must be determined by your doctor. 2 to 8 years of age: 2 grams once a day for one day. 8 to 14 years of age: 2 grams two times a day for one day. For oral suspension dosage form: For common roundworms or pinworms: Adults and teenagers—1.8 grams every four hours for a total of three doses in one day. Treatment may need to be repeated in two weeks. Children—Dose is based on age. Treatment may need to be repeated in two weeks. Up to 2 years of age: 600 milligrams (mg) every four hours for a total of three doses in one day. 2 to 8 years of age: 1.2 grams every six hours for a total of two doses in one day. 8 to 14 years of age: 1.2 grams every four hours for a total of three doses in one day. For tablet dosage form: For common roundworms: Adults and teenagers—3.5 grams (piperazine hexahydrate) per day for two days in a row. Treatment may need to be repeated in one week. Children—Dose is based on body weight and must be determined by your doctor. However, the usual dose is 75 mg (piperazine hexahydrate) per kilogram (34 mg per pound) of body weight per day for two days in a row. Treatment may need to be repeated in one week. For pinworms: Adults and children—Dose is based on body weight and must be determined by your doctor. However, the usual dose is 65 mg (piperazine hexahydrate) per kilogram (29.5 mg per pound) of body weight per day for seven days in a row. Treatment may need to be repeated in one week. Missed Dose If you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Thu Jul 06 11:28:08 UTC 2023
Edited
by admin
on Thu Jul 06 11:28:08 UTC 2023
Record UNII
V1FWC6DPTK
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PIPERAZINE HYDROBROMIDE
Systematic Name English
PIPERAZINE, HYDROBROMIDE (1:1)
Systematic Name English
PIPERAZINE, MONOHYDROBROMIDE
Common Name English
Code System Code Type Description
FDA UNII
V1FWC6DPTK
Created by admin on Thu Jul 06 11:28:08 UTC 2023 , Edited by admin on Thu Jul 06 11:28:08 UTC 2023
PRIMARY
PUBCHEM
3014804
Created by admin on Thu Jul 06 11:28:08 UTC 2023 , Edited by admin on Thu Jul 06 11:28:08 UTC 2023
PRIMARY
CAS
59813-07-9
Created by admin on Thu Jul 06 11:28:08 UTC 2023 , Edited by admin on Thu Jul 06 11:28:08 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE